文献速递其他结缔组织病

高通量血浆蛋白质组学揭示系统性硬化症相关间质性肺病及进展性肺纤维化的循环生物标志物

High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2026-07-23

本研究采用无偏蛋白质组学方法,在202例系统性硬化症(SSc)患者中识别与SSc相关间质性肺病(SSc-ILD)及进展性肺纤维化(SSc-PPF)相关的血浆生物标志物,并在多中心独立队列中验证其预测价值。结果显示SP-D在SSc-ILD中升高,MMP-8在SSc-PPF中升高,且MMP-8可独立预测SSc-PPF并提升临床变量模型的性能。

要点

  • SP-D在SSc-ILD患者中显著高于无ILD的SSc患者。
  • MMP-8在SSc-PPF患者中显著高于非进展性肺纤维化患者。
  • MMP-8可独立预测SSc-PPF并改善临床变量模型的预测性能。

核心结论

  • SP-D和MMP-8分别是诊断SSc-ILD和预测SSc-PPF的候选生物标志物。
  • 多中心队列验证支持其用于临床风险分层的相关性。

研究设计与样本

  • 研究纳入202例SSc患者,包括发现队列45例和复制队列157例,来自巴黎、波尔多、利兹3个中心。
  • 采用基于质谱的蛋白质组学在发现队列中识别候选生物标志物,并用ELISA在复制队列中评估顶级候选标志物。
  • 患者按ILD状态(SSc无ILD vs SSc-ILD)和ILD进展(SSc非进展性肺纤维化 vs SSc-PPF)分层,SSc-PPF按INBUILD标准定义。

主要发现

  • 共定量1507种蛋白质,其中44种与SSc-ILD相关,51种与SSc-PPF相关。
  • 五个候选标志物进入ELISA验证,其中SP-D和MMP-8成功复制。
  • 在合并队列中,SP-D在SSc-ILD中较SSc无ILD升高(17.36 ± 11.99 vs 9.49 ± 7.92 ng/mL;P < .0001)。
  • MMP-8在SSc-PPF中较SSc非进展性肺纤维化升高(17.67 ± 12.45 vs 10.77 ± 10.92 ng/mL;P < .001)。
  • MMP-8对PPF的预后价值在来自东京和米兰的另一113例患者队列中进一步复制。

关键数值与推荐

  • SSc-PPF按INBUILD标准定义。
  • SP-D在SSc-ILD vs SSc无ILD的合并队列中为17.36 ± 11.99 vs 9.49 ± 7.92 ng/mL(P < .0001)。
  • MMP-8在SSc-PPF vs SSc非进展性肺纤维化的合并队列中为17.67 ± 12.45 vs 10.77 ± 10.92 ng/mL(P < .001)。

临床怎么用

  • SP-D可作为辅助诊断SSc-ILD的循环生物标志物。
  • MMP-8可用于预测SSc-PPF并改善临床变量模型的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to identify plasma biomarkers associated with systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (SSc-PPF) using an unbiased proteomic approach, and to assess their predictive value across independent cohorts. METHODS: Plasma from 202 patients with SSc was analysed, including a discovery cohort (n = 45) and a replication cohort (n = 157) from 3 centres (Paris, Bordeaux, Leeds). Patients were stratified by ILD status (SSc without ILD [SSc-NoILD] vs SSc-ILD) and ILD progression (SSc with nonprogressive pulmonary fibrosis [SSc-NoPPF] vs SSc-PPF), with SSc-PPF defined according to INBUILD criteria. Mass spectrometry-based proteomics identified candidate biomarkers in the discovery cohort. Top candidates were evaluated by enzyme-linked immunosorbent assay (ELISA) in the replication cohort. Differential expression, pathway enrichment, and predictive performance analyses were performed. RESULTS: A total of 1507 proteins were quantified, of which 44 and 51 were associated with SSc-ILD and SSc-PPF, respectively. Five candidates progressed to ELISA validation, among which surfactant protein D (SP-D) and matrix metalloproteinase 8 (MMP-8) were successfully replicated. In the combined cohort, SP-D was elevated in SSc-ILD vs SSc-NoILD (17.36 ± 11.99 vs 9.49 ± 7.92 ng/mL; P < .0001). MMP-8 was higher in SSc-PPF vs SSc-NoPPF (17.67 ± 12.45 vs 10.77 ± 10.92 ng/mL; P < .001). Its prognostic value for PPF was further replicated in another cohort of 113 patients from Tokyo and Milan. In combined analyses, MMP-8 independently predicted SSc-PPF and improved performance when added to clinical variables. CONCLUSIONS: SP-D and MMP-8 emerge as candidate biomarkers for diagnosing SSc-ILD and predicting SSc-PPF, respectively. Their validation across multicentric cohorts supports their relevance for clinical risk stratification.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gerges E, Cauvet A, Guedot M, et al. High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis. Ann Rheum Dis. 2026. PMID: 42493308. doi:10.1016/j.ard.2026.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。